Archives of Pharmacal Research最新文献_第2页

C-phycocyanin reinforces autophagy to block pulmonary fibrogenesis by inhibiting lncIAPF biogenesis C-phycocyanin 可抑制 lncIAPF 的生物生成，从而加强自噬作用，阻止肺纤维化。

IF 6.9 3区医学

Archives of Pharmacal Research Pub Date : 2024-07-22 DOI: 10.1007/s12272-024-01508-y

Wenjie Hu, Yujie Wang, Huiling Yang, Leiming Zhang, Bo Liu, Yunxia Ji, Xiaodong Song, Changjun Lv, Songzi Zhang

{"title":"C-phycocyanin reinforces autophagy to block pulmonary fibrogenesis by inhibiting lncIAPF biogenesis","authors":"Wenjie Hu, Yujie Wang, Huiling Yang, Leiming Zhang, Bo Liu, Yunxia Ji, Xiaodong Song, Changjun Lv, Songzi Zhang","doi":"10.1007/s12272-024-01508-y","DOIUrl":"10.1007/s12272-024-01508-y","url":null,"abstract":"<div><p>Pulmonary fibrosis is a chronic and irreversible progressive lung disease caused by various factors, such as age and environmental pollution. With countries stepping into an aging society and the seriousness of environmental pollution caused by global industrialization, the incidence of pulmonary fibrosis is annually increasing. However, no effective drug is available for pulmonary fibrosis treatment. C-phycocyanin (C-PC), extracted from blue-green algae, has good water solubility and antioxidation. This study elucidated that C-PC reinforces autophagy to block pulmonary fibrogenesis by inhibiting long noncoding RNA (lncRNA) biogenesis in vivo and in vitro. Cleavage under targets and release using nuclease (CUT & RUN)-PCR, co-immunoprecipitation (Co-IP), and nuclear–cytoplasmic separation experiments clarified that C-PC blocked the nuclear translocation of activating transcription factor 3 (ATF3) to prevent the binding between ATF3 and transcription factor Smad3, thereby hindering lncIAPF transcription. Human antigen R (HuR) truncation experiment and RNA binding protein immunoprecipitation (RIP) were then performed to identify the binding domain with lncIAPF in the 244–322 aa of HuR. lncIAPF exerted its profibrogenic function through the binding protein HuR, a negative regulator of autophagy. In summary, C-PC promoted autophagy via down-regulating the lncIAPF–HuR-mediated signal pathway to alleviate pulmonary fibrosis, showing its potential as a drug for treating pulmonary fibrosis. Exploring how C-PC interacts with biological molecules will help us understand the mechanism of this drug and provide valuable target genes to design new drugs.</p></div>","PeriodicalId":8287,"journal":{"name":"Archives of Pharmacal Research","volume":"47 7","pages":"659 - 674"},"PeriodicalIF":6.9,"publicationDate":"2024-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11300487/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141747329","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Dual roles of myeloid-derived suppressor cells in various diseases: a review 髓源性抑制细胞在各种疾病中的双重作用：综述。

IF 6.9 3区医学

Archives of Pharmacal Research Pub Date : 2024-07-15 DOI: 10.1007/s12272-024-01504-2

Mahesh Raj Nepal, Sajita Shah, Kyu-Tae Kang

{"title":"Dual roles of myeloid-derived suppressor cells in various diseases: a review","authors":"Mahesh Raj Nepal, Sajita Shah, Kyu-Tae Kang","doi":"10.1007/s12272-024-01504-2","DOIUrl":"10.1007/s12272-024-01504-2","url":null,"abstract":"<div><p>Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of cells that originate from bone marrow stem cells. In pathological conditions, such as autoimmune disorders, allergies, infections, and cancer, normal myelopoiesis is altered to facilitate the formation of MDSCs. MDSCs were first shown to promote cancer initiation and progression by immunosuppression with the assistance of various chemokines and cytokines. Recently, various studies have demonstrated that MDSCs play two distinct roles depending on the physiological and pathological conditions. MDSCs have protective roles in autoimmune disorders (such as uveoretinitis, multiple sclerosis, rheumatoid arthritis, ankylosing spondylitis, type 1 diabetes, autoimmune hepatitis, inflammatory bowel disease, alopecia areata, and systemic lupus erythematosus), allergies, and organ transplantation. However, they play negative roles in infections and various cancers. Several immunosuppressive functions and mechanisms of MDSCs have been determined in different disease conditions. This review comprehensively discusses the associations between MDSCs and various pathological conditions and briefly describes therapeutic approaches.</p></div>","PeriodicalId":8287,"journal":{"name":"Archives of Pharmacal Research","volume":"47 7","pages":"597 - 616"},"PeriodicalIF":6.9,"publicationDate":"2024-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141615836","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Implications of inflammatory cell death-PANoptosis in health and disease 炎性细胞死亡--泛凋亡对健康和疾病的影响。

IF 6.9 3区医学

Archives of Pharmacal Research Pub Date : 2024-07-10 DOI: 10.1007/s12272-024-01506-0

Hyun Bae, Yeonseo Jang, Rajendra Karki, Joo-Hui Han

引用次数: 0

Dihydroartemisinin inhibits follicular helper T and B cells: implications for systemic lupus erythematosus treatment 双氢青蒿素抑制滤泡辅助 T 细胞和 B 细胞：对治疗系统性红斑狼疮的影响。

IF 6.9 3区医学

Archives of Pharmacal Research Pub Date : 2024-07-08 DOI: 10.1007/s12272-024-01505-1

Xiaoyi Shi, Tao Liao, Ye Chen, Jingrong Chen, Yan Liu, Jun Zhao, Junlong Dang, Qipeng Sun, Yunfeng Pan

{"title":"Dihydroartemisinin inhibits follicular helper T and B cells: implications for systemic lupus erythematosus treatment","authors":"Xiaoyi Shi, Tao Liao, Ye Chen, Jingrong Chen, Yan Liu, Jun Zhao, Junlong Dang, Qipeng Sun, Yunfeng Pan","doi":"10.1007/s12272-024-01505-1","DOIUrl":"10.1007/s12272-024-01505-1","url":null,"abstract":"<div><p>Systemic lupus erythematosus (SLE) is a common autoimmune disease, and its pathogenesis mainly involves the aberrant activation of B cells through follicular helper T (Tfh) cells to produce pathogenic antibodies, which requires more effective and safe treatment methods. Dihydroartemisinin (DHA) is the main active ingredient of artemisinin and has immunosuppressive effects. In this study, in vitro experiments confirmed that DHA inhibited Tfh cell induction and weakened its auxiliary function in B cell differentiation; furthermore, DHA directly inhibited B cell activation, differentiation, and antibody production. Furthermore, a mouse model of SLE was established, and we confirmed that DHA significantly reduced the symptoms of SLE and lupus nephritis, and decreased serum immunoglobulin (Ig)G, IgM, IgA, and anti-dsDNA levels. Moreover, DHA reduced the frequencies of total Tfh cells, activated Tfh cells, and B cell lymphoma 6, and interleukin (IL)-21 levels in Tfh cells from the spleen and lymph nodes, as well as the levels of B cells, germinal center B cells, and plasma cells in the spleen, lymph nodes, and kidneys. Additionally, DHA inhibited Tfh cells by blocking IL-2-inducible T cell kinase (ITK) signaling and its downstream nuclear factor (NF)-κB, nuclear factor of activated T cell, and activating protein-1 pathways, and directly inhibited B cells by blocking Bruton’s tyrosine kinase (BTK) signaling and the downstream NF-κB and Myc pathways. Overall, our results demonstrated that DHA inhibited Tfh cells by blocking ITK signaling and also directly inhibited B cells by blocking BTK signaling. Therefore, reducing the production of pathogenic antibodies might effectively treat SLE.</p></div>","PeriodicalId":8287,"journal":{"name":"Archives of Pharmacal Research","volume":"47 7","pages":"632 - 644"},"PeriodicalIF":6.9,"publicationDate":"2024-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141557956","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Correction: Antibody drug conjugates as targeted cancer therapy: past development, present challenges and future opportunities 更正：作为癌症靶向疗法的抗体药物共轭物：过去的发展、现在的挑战和未来的机遇。

IF 6.9 3区医学

Archives of Pharmacal Research Pub Date : 2024-06-26 DOI: 10.1007/s12272-024-01502-4

Ritwik Maiti, Bhumika Patel, Nrupesh Patel, Mehul Patel, Alkesh Patel, Nirav Dhanesha

引用次数: 0

Challenges and opportunities of developing small-molecule therapies for age-related macular degeneration 开发老年性黄斑变性小分子疗法的挑战与机遇。

IF 6.9 3区医学

Archives of Pharmacal Research Pub Date : 2024-06-20 DOI: 10.1007/s12272-024-01503-3

Xiang Fei, Sooyun Jung, Sangil Kwon, Jiweon Kim, Timothy W. Corson, Seung-Yong Seo

{"title":"Challenges and opportunities of developing small-molecule therapies for age-related macular degeneration","authors":"Xiang Fei, Sooyun Jung, Sangil Kwon, Jiweon Kim, Timothy W. Corson, Seung-Yong Seo","doi":"10.1007/s12272-024-01503-3","DOIUrl":"10.1007/s12272-024-01503-3","url":null,"abstract":"<div><p>Age-related macular degeneration (AMD) is the leading cause of vision loss in senior adults. The disease can be categorized into two types: wet AMD and dry AMD. Wet AMD, also known as exudative or neovascular AMD, is less common but more severe than dry AMD and is responsible for 90% of the visual impairment caused by AMD and affects 20 million people worldwide. Current treatment options mainly involve biologics that inhibit the vascular endothelial growth factor or complement pathways. However, these treatments have limitations such as high cost, injection-related risks, and limited efficacy. Therefore, new therapeutic targets and strategies have been explored to improve the outcomes of patients with AMD. A promising approach is the use of small-molecule drugs that modulate different factors involved in AMD pathogenesis, such as tyrosine kinases and integrins. Small-molecule drugs offer advantages, such as oral administration, low cost, good penetration, and increased specificity for the treatment of wet and dry AMD. This review summarizes the current status and prospects of small-molecule drugs for the treatment of wet AMD. These advances are expected to support the development of effective and targeted treatments for patients with AMD.</p></div>","PeriodicalId":8287,"journal":{"name":"Archives of Pharmacal Research","volume":"47 6","pages":"538 - 557"},"PeriodicalIF":6.9,"publicationDate":"2024-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141431232","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Interplay between YAP/TAZ and metabolic dysfunction-associated steatotic liver disease progression YAP/TAZ与代谢功能障碍相关脂肪性肝病进展之间的相互作用

IF 6.9 3区医学

Archives of Pharmacal Research Pub Date : 2024-06-14 DOI: 10.1007/s12272-024-01501-5

Na Young Lee, Myeung Gi Choi, Eui Jin Lee, Ja Hyun Koo

{"title":"Interplay between YAP/TAZ and metabolic dysfunction-associated steatotic liver disease progression","authors":"Na Young Lee, Myeung Gi Choi, Eui Jin Lee, Ja Hyun Koo","doi":"10.1007/s12272-024-01501-5","DOIUrl":"10.1007/s12272-024-01501-5","url":null,"abstract":"<div><p>Metabolic dysfunction-associated steatotic liver disease (MASLD) is becoming an increasingly pressing global health challenge, with increasing mortality rates showing an upward trend. Two million deaths occur annually from cirrhosis and liver cancer together each year. Yes-associated protein (YAP) and transcriptional coactivator with PDZ-binding motif (TAZ), key effectors of the Hippo signaling pathway, critically regulate tissue homeostasis and disease progression in the liver. While initial studies have shown that YAP expression is normally restricted to cholangiocytes in healthy livers, the activation of YAP/TAZ is observed in other hepatic cells during chronic liver disease. The disease-driven dysregulation of YAP/TAZ appears to be a critical element in the MASLD progression, contributing to hepatocyte dysfunction, inflammation, and fibrosis. In this study, we focused on the complex roles of YAP/TAZ in MASLD and explored how the YAP/TAZ dysregulation of YAP/TAZ drives steatosis, inflammation, fibrosis, and cirrhosis. Finally, the cell-type-specific functions of YAP/TAZ in different types of hepatic cells, such as hepatocytes, hepatic stellate cells, hepatic macrophages, and biliary epithelial cells are discussed, highlighting the multifaceted impact of YAP/TAZ on liver physiology and pathology.</p></div>","PeriodicalId":8287,"journal":{"name":"Archives of Pharmacal Research","volume":"47 6","pages":"558 - 570"},"PeriodicalIF":6.9,"publicationDate":"2024-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11217110/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141316670","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Antibacterial properties of natural products from marine fungi reported between 2012 and 2023: a review 2012 年至 2023 年间报道的海洋真菌天然产品的抗菌特性：综述。

IF 6.9 3区医学

Archives of Pharmacal Research Pub Date : 2024-06-08 DOI: 10.1007/s12272-024-01500-6

Ping Wang, Xiaomei Huang, Chenyuan Jiang, Rushuang Yang, Jialing Wu, Yinghui Liu, Shuangshuang Feng, Tingting Wang

{"title":"Antibacterial properties of natural products from marine fungi reported between 2012 and 2023: a review","authors":"Ping Wang, Xiaomei Huang, Chenyuan Jiang, Rushuang Yang, Jialing Wu, Yinghui Liu, Shuangshuang Feng, Tingting Wang","doi":"10.1007/s12272-024-01500-6","DOIUrl":"10.1007/s12272-024-01500-6","url":null,"abstract":"<div><p>The oceans are rich in diverse microorganisms, animals, and plants. This vast biological complexity is a major source of unique secondary metabolites. In particular, marine fungi are a promising source of compounds with unique structures and potent antibacterial properties. Over the last decade, substantial progress has been made to identify these valuable antibacterial agents. This review summarizes the chemical structures and antibacterial activities of 223 compounds identified between 2012 and 2023. These compounds, effective against various bacteria including drug-resistant strains such as methicillin-resistant <i>Staphylococcus aureus</i>, exhibit strong potential as antibacterial therapeutics. The review also highlights the relevant challenges in transitioning from drug discovery to product commercialization. Emerging technologies such as metagenomics and synthetic biology are proposed as viable solutions. This paper sets the stage for further research on antibacterial compounds derived from marine fungi and advocates a multidisciplinary approach to combat drug-resistant bacteria.</p></div>","PeriodicalId":8287,"journal":{"name":"Archives of Pharmacal Research","volume":"47 6","pages":"505 - 537"},"PeriodicalIF":6.9,"publicationDate":"2024-06-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141293095","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Exploring molecular mechanisms, therapeutic strategies, and clinical manifestations of Huntington’s disease 探索亨廷顿氏病的分子机制、治疗策略和临床表现。

IF 6.9 3区医学

Archives of Pharmacal Research Pub Date : 2024-05-19 DOI: 10.1007/s12272-024-01499-w

Alaa Shafie, Amal Adnan Ashour, Saleha Anwar, Farah Anjum, Md. Imtaiyaz Hassan

{"title":"Exploring molecular mechanisms, therapeutic strategies, and clinical manifestations of Huntington’s disease","authors":"Alaa Shafie, Amal Adnan Ashour, Saleha Anwar, Farah Anjum, Md. Imtaiyaz Hassan","doi":"10.1007/s12272-024-01499-w","DOIUrl":"10.1007/s12272-024-01499-w","url":null,"abstract":"<div><p>Huntington’s disease (HD) is a paradigm of a genetic neurodegenerative disorder characterized by the expansion of CAG repeats in the <i>HTT</i> gene. This extensive review investigates the molecular complexities of HD by highlighting the pathogenic mechanisms initiated by the mutant huntingtin protein. Adverse outcomes of HD include mitochondrial dysfunction, compromised protein clearance, and disruption of intracellular signaling, consequently contributing to the gradual deterioration of neurons. Numerous therapeutic strategies, particularly precision medicine, are currently used for HD management. Antisense oligonucleotides, such as Tominersen, play a leading role in targeting and modulating the expression of mutant huntingtin. Despite the promise of these therapies, challenges persist, particularly in improving delivery systems and the necessity for long-term safety assessments. Considering the future landscape, the review delineates promising directions for HD research and treatment. Innovations such as Clustered regularly interspaced short palindromic repeats associated system therapies <b>(</b>CRISPR)-based genome editing and emerging neuroprotective approaches present unprecedented opportunities for intervention. Collaborative interdisciplinary endeavors and a more insightful understanding of HD pathogenesis are on the verge of reshaping the therapeutic landscape. As we navigate the intricate landscape of HD, this review serves as a guide for unraveling the intricacies of this disease and progressing toward transformative treatments.</p></div>","PeriodicalId":8287,"journal":{"name":"Archives of Pharmacal Research","volume":"47 6","pages":"571 - 595"},"PeriodicalIF":6.9,"publicationDate":"2024-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141065283","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Phytochemical and pharmacological properties of the genus Tamarix: a comprehensive review 柽柳属的植物化学和药理特性：全面综述。

IF 6.9 3区医学

Archives of Pharmacal Research Pub Date : 2024-05-15 DOI: 10.1007/s12272-024-01498-x

Fangjie Li, Wenli Xie, Xianrui Ding, Kuo Xu, Xianjun Fu

{"title":"Phytochemical and pharmacological properties of the genus Tamarix: a comprehensive review","authors":"Fangjie Li, Wenli Xie, Xianrui Ding, Kuo Xu, Xianjun Fu","doi":"10.1007/s12272-024-01498-x","DOIUrl":"10.1007/s12272-024-01498-x","url":null,"abstract":"<div><p>The genus <i>Tamarix</i> in the Tamaricaceae family consists of more than 100 species of halophyte plants worldwide that are mainly used to improve saline-alkali land and for coastal windbreaks, sand fixation, and afforestation in arid areas. A considerable number of species in this genus are also used as traditional medicines to treat various human diseases, especially in Asian and African countries. This review presents a comprehensive summary of 655 naturally occurring compounds derived from the genus <i>Tamarix</i>, categorized into flavonoids (18.0%), phenols (13.9%), tannins (9.3%), terpenoids (10.5%), essential oils (31.0%), and others (17.3%). The investigation revealed that the crude extracts and phytochemicals of this genus exhibited significant therapeutic potential, including anti-inflammatory, anti-Alzheimer, anticancer, antidiabetic, antibacterial, and antifungal activities. Six species of <i>Tamarix</i> have anticancer effects by causing cancer cell death, inducing autophagy, and stopping cell division. Seven species from the same genus have the potential for treating diabetes by inhibiting α-glycosidase activity, suppressing human islet amyloid polypeptide, regulating blood glucose levels, and modulating autophagy or inflammation. The focus on antibacterial and antidiabetic effects is due to the presence of volatile oil and flavonoid components. Extensive research has been conducted on the biological activity of 30 constituents, including 15 flavonoids, 5 phenols, 3 terpenoids, 1 tannin, and 6 others. Therefore, future research should thoroughly study the mechanisms of action of these and similar compounds. This is the most comprehensive review of the phytochemistry and pharmacological properties of <i>Tamarix</i> species, with a critical assessment of the current state of knowledge.</p></div>","PeriodicalId":8287,"journal":{"name":"Archives of Pharmacal Research","volume":"47 5","pages":"410 - 441"},"PeriodicalIF":6.9,"publicationDate":"2024-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140943971","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0